 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- irinotecan liposomal / CSPC Pharma
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4713;
Combined use of SG001 further improved clinical outcome in these pts without increased toxicity. Combination of liposomal irinotecan, 5-FU, LV and PD-1 inhibitor is a treatment strategy which is worthy of further exploration.
- irinotecan liposomal / CSPC Pharma
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer. (Hall A; Poster Bd #: 121) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3871;
P2
Combination of liposomal irinotecan, 5-FU, LV and PD-1 inhibitor is a treatment strategy which is worthy of further exploration. Patients with unresectable locally advanced or metastatic pancreatic cancer were randomly assigned (2:1) to receive NALIRIFOX (HE072 50 mg/m
- irinotecan liposomal / CSPC Pharma
A phase 1 study of liposomal irinotecan in patients with advanced breast cancer. (Hall A; Poster Bd #: 58) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2510;
P1
70 mg/m 2 Q2W was determined as the RP2D. Further clinical trials are under plan.
- ||| irinotecan liposomal / CSPC Pharma
New trial: Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer (clinicaltrials.gov) - Apr 11, 2024
P=N/A, N=53, Recruiting, Sponsor: Kuirong Jiang
- |||||| irinotecan liposomal / CSPC Pharma
New trial, Metastases: Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV (clinicaltrials.gov) - Feb 28, 2024
P=N/A, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| irinotecan liposomal / CSPC Pharma, Avastin (bevacizumab) / Roche
New P1 trial, Metastases: Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 25, 2024
P1, N=78, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- || Duoenda (mitoxantrone liposomal) / CSPC Pharma
Enrollment change: Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors (clinicaltrials.gov) - Aug 18, 2023
P1, N=68, Recruiting, Sponsor: Sun Yat-sen University
Further clinical trials are under plan. N=33 --> 68
- || Duoenda (mitoxantrone liposomal) / CSPC Pharma
New P1 trial: Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors (clinicaltrials.gov) - Nov 17, 2022
P1, N=33, Recruiting, Sponsor: Sun Yat-sen University
- || irinotecan liposomal / CSPC Pharma
Trial completion date, Trial primary completion date, Metastases: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Sep 19, 2021
P2, N=66, Not yet recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
N=33 --> 68 Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
- |||| irinotecan liposomal / CSPC Pharma
New P2 trial, Metastases: Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 17, 2021
P2, N=153, Not yet recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- |||| irinotecan liposomal / CSPC Pharma
New P2 trial, Metastases: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Aug 17, 2021
P2, N=66, Not yet recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- ||| irinotecan liposomal / CSPC Pharma
New P1 trial, Metastases: Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance (clinicaltrials.gov) - Jan 27, 2021
P1, N=136, Not yet recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- |||| irinotecan liposomal / CSPC Pharma
New P2 trial: Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Jan 26, 2021
P2, N=80, Not yet recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- || irinotecan liposomal / CSPC Pharma
New P1 trial, Metastases: Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. (clinicaltrials.gov) - Jul 21, 2020
P1, N=48, Recruiting, Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.